자궁경부암 예방 백신의 현황과 전망 = Human papillomavirus vaccines: current status and perspectives

참고문헌 (Reference)

1 "and human papilomavirus E7 protein share the capacity to disrupt the interaction betwen transcription factor E2F and the retinoblastoma gene product" ade (ade): 4549-53, natlacadsciusa1992

2 "Viruses in human cancers" 1991 254 : 1167-73,

3 "Vaccination with yeast-expressed cotontail rabbit papilomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papiloma formation" 13 : 1509-1514, 1995

4 "The promise of global cervical cancer prevention" 353 : 2101-2104, 2005

5 "The p53 network" 273 : 1-4, 1998

6 "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilomavirus types 16 and 18" 367 : 1247-1255, 2006

7 "Prevalence of human papillomavirus in cervical cancer" 87 : 769-802, 1995

8 "Preparing for the introduction of HPV vaccines" 2006

9 "Papilomavirus L1 major capsid protein self-assembles into virus-like particles that are highly imunogenic" 12180-4,

10 "Localization of the E6-AP regions that direct human papilomavirus E6 binding asociation with p53 and ubiquitination of asociated proteins" 부인종양 17 (부인종양 17): 4918-27, molcelbiol1993

11 "In vitro infection and type-restricted antibody-mediated neutralization of authentic human papilomavirus type 16" 72 : 959-964, 1998

12 "In vitro generation and type-specific neutralization of a human papilomavirus type 16 virion pseudotype" 70 : 5875-5883, 1996

13 "Imunization with viruslike particles from cotontail rabbit papilomavirus (CRPV) can protect against experimental CRPV infection" 69 : 3959-3963, 1995

14 "Human papilomavirus infection of the cervix Relative risk associations of fifteen common anogenital types" Lorincz AT 328-37, obstetgynecol1992

15 "Human papilomavirus genotyping by the DNA chip in the cervical neoplasia" 23 : 119-125, 2004

16 "Human papilomavirus and genital cancer" 1987 48 : 113-47,

17 "High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/1/16/18 L1 virus- like particle vaccine through 5 years of follow-up" 95 : 1459-1466, 2006

18 "HPV vaccines" 20 : 279-293, 2006

19 "Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles" 1991 185 : 251-7,

20 "Epidemiologic classification of human papillomavirus types associated with cervical cancer" 348 : 518-527, 2003

21 "Diferentiation-dependent up-regulation of the human pa-pillomavirus E7 gene reactivates cellular DNA replication in suprabasal diferentiated keratinocytes" 9 : 2335-2349, 1995

22 "Degradation of the retinoblastoma tumor suppressor by the human papilomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7" 75 : 7583-7591, 2001

23 "Cellular transformation by papillo-mavirus oncoproteins" 1993 1155 : 323-5,

24 "Cancer burden in the year 2000" 37 : 4-66, 2001

25 "Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cels" 20 : 4740-4749, 2001

26 "ACIP Provisional Recomendations for the Use of Quadri-valent HPV Vaccine 2006 June" 2006

27 "A controlled trial of a human papillomavirus type 16 vaccine" 347 : 1645-1651, 2002